Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts

被引:31
作者
Giorgini, A.
Noble, A.
机构
[1] Kings Coll London, Dept Asthma Allergy & Resp Sci, MRC, London SE1 9RT, England
[2] Asthma UK Ctr Allerg Mech Asthma, London, England
基金
英国医学研究理事会;
关键词
alloreactivity; suppression; dexamethasone;
D O I
10.1189/jlb.0407227
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
CD4(+)CD25(+) regulatory T cells (Tregs) are well known to suppress immunopathology induced in lymphopenic animals following T cell reconstitution, including acute graft-versus-host disease (GVHD) post-bone marrow transplantation. The regulatory potential of this subset in nonlymphopenic hosts and in chronic, Th2-mediated GVHD is less clear. We have generated alloantigen-specific cells from CD4+CD25+ populations stimulated with MHC-disparate dendritic cells and found them to express a stable Treg forkhead box p3(+) phenotype with enhanced suppressive activity mediated by cell contact. When transferred into nonlymphopenic F1 hosts, nonspecific Tregs proliferated as rapidly as CD4(+)CD25(-) cells but displayed distinct growth kinetics in vitro. Tregs, expanded in response to alloantigen in vitro, displayed greatly enhanced suppressive activity, which was partially antigen-specific. They were effective inhibitors of chronic GVHD, blocking donor cell engraftment, splenomegaly, autoantibody production, and glomerulonephritis. CD25(+) and CD25(-) cells were equally susceptible to inhibition by immunosuppressive drugs targeting TCR signaling and rapamycin, but Tregs were resistant to inhibition by dexamethasone. The data indicate that alloantigen-driven expansion, rather than homeostatic proliferation, is key to the effectiveness of CD4(+)CD25(+) Tregs in GVHD and suggest that cellular therapy with alloantigen-induced Tregs in combination with glucocorticoid treatment would be effective in prevention of chronic GVHD after immune reconstitution.
引用
收藏
页码:1053 / 1061
页数:9
相关论文
共 55 条
  • [1] T cell regulation as a side effect of homeostasis and competition
    Barthlott, T
    Kassiotis, G
    Stockinger, B
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (04) : 451 - 460
  • [2] Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
    Battaglia, M
    Stabilini, A
    Roncarolo, MG
    [J]. BLOOD, 2005, 105 (12) : 4743 - 4748
  • [3] Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance
    Battaglia, M
    Stabilini, A
    Draghici, E
    Gregori, S
    Mocchetti, C
    Bonifacio, E
    Roncarolo, MG
    [J]. DIABETES, 2006, 55 (01) : 40 - 49
  • [4] Cederbom L, 2000, EUR J IMMUNOL, V30, P1538, DOI 10.1002/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO
  • [5] 2-X
  • [6] Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3
    Chen, WJ
    Jin, WW
    Hardegen, N
    Lei, KJ
    Li, L
    Marinos, N
    McGrady, G
    Wahl, SM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (12) : 1875 - 1886
  • [7] Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death
    Chen, X
    Murakami, T
    Oppenheim, JJ
    Howard, DMZ
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (03) : 859 - 869
  • [8] CD4+CD25+ immunoregulatory T cells:: New therapeutics for graft-versus-host disease
    Cohen, JL
    Trenado, A
    Vasey, D
    Klatzmann, D
    Salomon, BL
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (03) : 401 - 406
  • [9] Developments in T-cell depletion of allogeneic stem cell grafts
    Cornelissen, JJ
    Löwenberg, B
    [J]. CURRENT OPINION IN HEMATOLOGY, 2000, 7 (06) : 348 - 352
  • [10] DEWIT D, 1993, J IMMUNOL, V150, P361